# Vergent Bioscience

Source: https://onco.cc/companies/vergent-bioscience/  
OnCo record `vergent-bioscience` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vergent Bioscience is testing an injectable dye that makes lung tumours glow during keyhole and robotic surgery, so surgeons can find small or hidden tumours and check that all of the cancer has been removed.

## Summary

Vergent Bioscience is a clinical-stage company in Minneapolis developing abenacianine for injection (VGT-309), a tumour-targeted fluorescent imaging agent for minimally invasive and robotic-assisted cancer surgery. Abenacianine is a quenched activity-based probe that binds cathepsin proteases overexpressed in tumours and fluoresces in the near-infrared range. The lead indication is lung cancer. The phase 2 VISUALIZE trial completed enrolment in November 2024 and 2025 results showed improved tumour visibility during lung surgery; the FDA granted Fast Track designation in January 2025 and the pivotal phase 3 VISUALIZE 2 study began in March 2026. The company states it has raised more than USD 34 million; SEC Form D filings record equity sales of USD 21.5 million in 2022 and USD 18.7 million in October 2025 plus smaller convertible note offerings. Abenacianine is investigational and not approved for any indication.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Minneapolis, MN
- Type: biotech
- Website: https://www.vergentbio.com/

## Notes

- Investor names are shown as logos on the investors page and could not be read from the fetched text, so investors is empty. Named round letters (Series A/B) were not found in press releases; Form D totals are used instead. The cathepsin mechanism is from general knowledge of VGT-309 rather than the fetched pages. Founding year not stated.

## Sources

- Official website: https://www.vergentbio.com/
- Press releases: https://www.vergentbio.com/press-releases
- Investors page (over USD 34 million raised): https://www.vergentbio.com/investors
- SEC Form D (Oct 2025): https://www.sec.gov/Archives/edgar/data/1741495/000174149525000004/primary_doc.xml
- SEC Form D (Aug 2022): https://www.sec.gov/Archives/edgar/data/1741495/000174149522000001/primary_doc.xml

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Imaging](https://onco.cc/fronts/imaging/), [Surgery & Interventional](https://onco.cc/fronts/surgery/)
- technologies: [Fluorescence-guided surgery](https://onco.cc/technologies/fluorescence-guided-surgery/), [Optical & fluorescence imaging](https://onco.cc/technologies/optical-imaging/)
- trials: [Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung](https://onco.cc/trials/nct07499674/)

---
JSON: https://onco.cc/api/v1/entities/vergent-bioscience.json